#United States #Genomics #Menlo Park #Oracle #MyOme

MyOme Partners with Oracle to Revolutionize Predictive Genomics

In an exciting development for the field of healthcare, MyOme, Inc. has partnered with Oracle to leverage advanced genomic risk prediction capabilities at a global scale. This collaboration aims to transform the traditional healthcare model, moving from reactive treatment to proactive health management. The platform will harness Oracle Cloud Infrastructure (OCI) to enhance MyOme's predictive genomic insights, making them accessible to healthcare providers worldwide.

Advancing Healthcare with Genomic Insights

MyOme, recognized as a leader in clinical whole-genome analysis and polygenic risk modeling, has announced that their predictive genomic insights platform is now available globally. This initiative combines MyOme's genomic expertise with the immense power and security of OCI, enabling healthcare professionals to identify individuals at high risk for preventable diseases earlier than ever.

Dr. Matt Rabinowitz, executive chairman at MyOme, emphasized the significance of this collaboration, stating, "Pairing MyOme's whole-genome platform with OCI's global infrastructure lets us identify people at high risk for preventable disease early enough to act on it." This integration aims to provide a comprehensive evaluation of each individual's genetic makeup alongside relevant clinical risk factors, offering a holistic view of a patient's health.

How It Works

MyOme applies an innovative approach by sequencing each individual’s entire genome only once. OCI's high-performance computing capabilities then analyze millions of genetic variants alongside clinical data, producing integrated polygenic risk scores for common and rare conditions such as coronary artery disease, type 2 diabetes, prostate cancer, and breast cancer. This method contrasts with conventional genetic testing, which typically focuses on a limited number of genes, thus providing broader clinical insights derived from a single sample.

The ability to query this genomic data continually allows healthcare professionals to monitor changes in a patient's health over time and adapt their preventive strategies as science evolves. As such, MyOme's approach not only enhances the accuracy of risk assessment but also democratizes access to critical health insights that can lead to timely interventions.

A Shift Toward Proactive Healthcare

This partnership will enable clinicians to make informed decisions about the right interventions at the most opportune moments. Dan Spellman, group vice president of AI and OCI at Oracle, remarked, "By making predictive genomics accessible, clinicians have more information to decide on the right intervention at the right time." This collaborative effort aims to elevate healthcare standards on a global scale.

About MyOme

Based in Menlo Park, California, MyOme is committed to helping families gain insights into their disease risk through clinical whole genome analysis. The company combines polygenic analysis with AI-driven technologies to integrate risk scores with established clinical predictors. By doing so, MyOme provides a comprehensive approach to assessing disease risk, which can significantly improve health outcomes and reduce healthcare expenses. As a certified laboratory under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), MyOme stands at the forefront of genomic healthcare solutions.

Conclusion

The MyOme and Oracle partnership signifies an important evolution in predictive genomics, promising to enhance global healthcare practices. With this collaboration, patients can expect a future where their genetic profiles inform proactive health strategies, ultimately leading to better health outcomes and enhanced quality of life.